Removing Neumann is a difficult decision for Son, who has long believed in WeWork and Neumann's vision to quickly expand the company.Technologyread more
The Kingdom and oil and gas industry have been slow to shore up defenses, raising red flags about the possibility of longer term fall-out in the region.Technologyread more
Datadog went public on Thursday and instantly hit a $10 billion valuation, becoming the fourth cloud software debut to reach that level this year.Technologyread more
There are challenges with Iran, North Korea, the Afghan Taliban, Israel and the Palestinians — not to mention a number of trade pacts.Politicsread more
Blackstone Executive Vice Chairman Tony James says he's less optimistic now than before that the U.S.-China trade war could be resolved, but even a smaller deal could help...World Economyread more
In his new memoir, "The Ride of a Lifetime," Iger explains why he decided against the deal to buy Twitter.Technologyread more
In perhaps Buffett's first televised profile, he explained a method of investing that prioritizes bargains and makes use of an occasional baseball analogy.Marketsread more
Gluskin Sheff's David Rosenberg reinforces his recession forecast following the Federal Reserve's September meeting.Futures Nowread more
"This would be the most profound violation of the presidential oath of office certainly during this presidency," House Intelligence Chair Adam Schiff said.Politicsread more
A 58% majority of registered voters express unease about voting for Trump, but slightly more say the same about Joe Biden and Bernie Sanders, while Elizabeth Warren fares only...Politicsread more
The massive market transformation this month that some on Wall Street called a "once in a decade opportunity" might have just been a one-off technical move because of taxes.Marketsread more
President Donald Trump's pick to head the U.S. Health and Human Services Department, Alex Azar, said "drug prices are too high" at a Senate confirmation hearing as he ducked a direct question on whether he ever had approved a price decrease while he was a top pharmaceuticals company executive.
Azar came under strong questioning from Sen. Ron Wyden, D-Ore., who noted that Azar had repeatedly approved price hikes while president of the U.S. subsidiary of drug giant Eli Lilly, and serving on the company's pricing committee.
Wyden noted that Lilly's drug Forteo, which is used to treat bone loss, saw a 164 percent price hike during Azar's tenure. Azar was president from 2012 to 2017.
"When you ran [the pricing committee] higher prices drove revenue for drug, after drug, after drug, even after demand for the products fell," Wyden said during the Senate Finance Committee hearing.
"As chairman of the drug pricing committee, did you ever lower the price — ever — of a Lilly drug sold in the United States?" Wyden asked.
Azar did not answer that question.
"Drug prices are too high," Azar said.
Wyden interjected, "Mr. Azar, that is not the question."
Azar then said, "I don't know there is any price of a branded drug product that has gone down."
"We can do things together," Azar told Wyden. "No one company's going to fix this system."
Wyden then said the record of the committee hearing should reflect that Azar confirmed he had never lowered the price of a drug while at Lilly.
Wyden had opened the hearing by noting the irony of Trump, who has said drug companies have gotten away with "murder" in raising pharmaceticul prices, nominating a pharma executive with "a documented history of raising prescription drug price
Azar later told Sen. Debbie Stabenow, D-Mich., that "all drug prices are too high in this country."
He told Stabenow that he would be willing to explore the question of whether Medicare Part B should have the power to negotiate drug prices, as currently does Medicare Part D, the prescription drug benefit program. Medicare Part B covers drug treatment administered in physicians' offices and outpatient settings.
Azar previously was general counsel and deputy secretary of HHS during the administration of President George W. Bush.
If approved, the Yale Law grad would oversee a department responsible for operating the nation's huge Medicare and Medicaid health coverage systems, as well as the Obamacare program that is strongly opposed by the Trump administration.
HHS' bailiwick also includes regulating the pharmaceuticals industry that Azar recently left.
Azar, 50, was tapped by Trump to succeed Dr. Tom Price, who resigned as HHS' chief in September after scathing reports about Price's repeated use of pricey private charter flights at taxpayer expense instead of using less expensive means of travel.
In an op-ed published Tuesday by news site STAT, two former Senate majority leaders, Republican Bill Frist and Democrat Tom Daschle, wrote that Azar's nomination meets a "high bar" for what the job of secretary of HHS requires.
"We know Alex to have the temperament, judgment, and necessary focus on practicality that is important to being a successful HHS secretary, even if we do not agree with him on every issue," Frist and Daschle wrote. "He has pledged to follow the law and abide by its restraints. And just as essential, he has promised to listen to stakeholders and work with Democrats as well as Republicans."
But on Monday, the Obamacare advocacy group Protect Our Care launched a digital ad campaign urging senators to vote against Azar's nomination.
"Azar has agreed to head up the GOP's war on health care, which has included ... a never-ending quest to repeal health care despite the fact that doing so raises premiums by double digits and removes protections for millions of Americans," Protect Our Care said in a statement announcing the ad.